Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Regenxbio Inc. (NASDAQ:RGNX) suffered another setback in its effort to bring RGX-121 to patients with Hunter syndrome.
Regenxbio Inc. (RGNX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 4,368,804 | $52,338,272 | 3.51% | |
| 2. | AQR Capital Management Cliff Asness | 1,378,358 | $16,512,730 | +32% | 0.01% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,284,950 | $15,393,701 | 0.01% | |
| 4. | Integral Health Asset Management Bhagwan Jay Rao | 800,000 | $9,584,000 | -47% | 0.38% |
| 5. | D E Shaw D. E. Shaw | 712,814 | $8,539,512 | +150% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.36 | 53,407 | $499,675.89 | 118,035 | 2026-08-27 | Filing | |
| $9.14 | 49,196 | $449,705.56 | 64,628 | 2026-08-26 | Filing | |
| $22.00 | 49,000 | $1,078,000.00 | 49,000 | 2015-09-22 | Filing | |
| $22.00 | 38,500 | $847,000.00 | 38,500 | 2015-09-22 | Filing | |
| $22.00 | 87,500 | $1,925,000.00 | 1,256,542 | 2015-09-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.64 | 2,161 | $29,476.04 | 213,009 | 2026-07-02 | Filing | |
| $12.86 | 36,725 | $472,283.50 | 213,009 | 2026-07-01 | Filing | |
| $11.04 | 19,608 | $216,472.32 | 213,009 | 2026-06-29 | Filing | |
| $11.02 | 15,309 | $168,705.18 | 232,617 | 2026-05-11 | Filing | |
| $10.35 | 5,124 | $53,033.40 | 247,926 | 2026-03-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 195,624 | $1,473,049 | 0.03% | |
| 2. | 47,729 | $386,128 | 0% | |
| 3. | 45,588 | $343,278 | 0% | |
| 4. | 4,664 | $35,120 | 0% | |
| 5. | 2,741 | $20,640 | 0% |
News See All
10 Best Gene Therapy Stocks to Buy in 2026
In this article, we will discuss the 10 Best Gene Therapy Stocks to Buy in 2026.
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2026 Earnings Call Transcript May 14, 2026REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations were $-1.36.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01.
REGENXBIO Inc. (RGNX): A Bull Case Theory
We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on RGNX.
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2025 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2025 Earnings Call Transcript November 6, 2025REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.19834, expectations were $-1.38.
REGENXBIO Publishes Preclinical Data Highlighting RGX-202's Potential for Duchenne Muscular Dystrophy
REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
REGENXBIO Inc. (RGNX): A Bull Case Theory
This stock is one of several featured in our latest research.
10 Promising SmallCap Stocks Under $1 Billion Market Cap
In this article, we look at 10 promising SmallCap stocks under $1 billion in market capitalization.
Hedge Fund Resource Center